Gadolinium mixed-micelles: Effect of the amphiphile on in vitro and in vivo efficacy in apolipoprotein E knockout mouse models of atherosclerosis

Magnetic Resonance in Medicine

Volumn 56, Issue 6, 2006, Pages 1336-1346

  Briley Saebo, Karen C ^a   Amirbekian, Vardan ^a,b   Mani, Venkatesh ^a   Aguinaldo, Juan Gilberto S ^a   Vucic, Esad ^a   Carpenter, David ^a   Amirbekian, Smbat ^a,c   Fayad, Zahl A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphiphiles; Atherosclerosis; Contrast agents; Mixed micelles; Nano particles

Indexed keywords

AMPHIPHILES; DISEASES; GADOLINIUM COMPOUNDS; LIPOPROTEINS; MAMMALS; NANOPARTICLES; PARTICLE SIZE; PHOSPHOLIPIDS;

APOLIPOPROTEIN E; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTRAST AGENT; FLUORESCENT LABELS; KNOCKOUT MICE; MIXED MICELLES; POST INJECTION;

MICELLES;

2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; AMPHOPHILE; APOLIPOPROTEIN E; CONTRAST MEDIUM; DIPALMITOYLPHOSPHATIDYLCHOLINE; FLUORESCENT DYE; GADOLINIUM; GADOLINIUM PENTETATE; PHOSPHOLIPID; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG RETENTION; DRUG UPTAKE; IMAGE ENHANCEMENT; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LIVER; MICELLE; MOUSE; NANOPARTICLE; NONHUMAN; PARTICLE SIZE; PERMEABILITY; PLASMA CLEARANCE; PLASMA HALF LIFE; SURFACE PROPERTY;

EID: 33845242770     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21094     Document Type: Article

References (69)

1. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull Jr W, Schwartz RS, Vogel R, Serrays PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003;108:1772-1778.
2. Libby P. Managing the risk of atherosclerosis: the role of high-density lipoprotein. Am J Cardiol 2001;88:3N-8N.
3. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996;7:330-335.
4. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995;25(Suppl 2):S9-S12.
5. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005;25:2054-2061.
6. Choudhury RP, Rong JX, Trogan E, Elmalem VI, Dansky HM, Breslow JL, Witztum JL, Fallon JT, Fisher EA. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol 2004;24:1904-1909.
7. Tsimikas S, Shaw PX. Non-invasive imaging of vulnerable plaques by molecular targeting of oxidized LDL with tagged oxidation-specific antibodies. J Cell Biochem 2002:138-146.
8. Tsimikas S, Strauss BH, Lau HK, Bergmark C, Curtiss LK, Miller E, Witztum JL. Pathophysiologic interrelationship of OxLDL and Lp(a) in human coronary plaque disruption and acute coronary syndromes. Atherosclerosis Suppl 2003;4:294-294.
9. Hayward JK, Davies AH, Lamont PM. Carotid plaque morphology: a review. Eur J Vasc Endovasc Surg 1995;9:368-374.
10. Davies JR, Rudd JH, Weissberg PL. Molecular and metabolic imaging of atherosclerosis. J Nucl Med 2004;45:1898-1907.
11. Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 2004;17:35-44.
12. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005;46:937-954.
13. Yuan C, Hatsukami TS, Cai J. MRI plaque tissue characterization and assessment of plaque stability. Stud Health Technol Inform 2005;113: 55-74.
14. Yuan C, Hatsukami TS, Obrien KD. High-resolution magnetic resonance imaging of normal and atherosclerotic human coronary arteries ex vivo: discrimination of plaque tissue components. J Invest Med 2001;49:491-499.
15. Yuan C, Kerwin WS. MRI of atherosclerosis. J Magn Reson Imaging 2004;19:710-719.
16. Yuan C, Mitsumori LM, Beach KW, Maravilla KR. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiology 2001;221:285-299.
17. Yuan C, Zhao XQ, Hatsukami TS. Quantitative evaluation of carotid atherosclerotic plaques by magnetic resonance imaging. Curr Atheroscler Rep 2002;4:351-357.
18. Itskovich W, Samber DD, Mani V, Aguinaldo JG, Fallon JT, Tang CY, Fuster V, Fayad ZA. Quantification of human atherosclerotic plaques using spatially enhanced cluster analysis of multicontrast-weighted magnetic resonance images. Magn Reson Med 2004;52:515-523.
19. Cai J, Hatsukami TS, Ferguson MS, Kerwin WS, Saam T, Chu B, Takaya N, Polissar NL, Yuan C. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation 2005;112:3437-3444.
20. Cai JM, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 2002;106: 1368-1373.
21. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov 2004;3:913-925.
22. Fayad ZA, Fuster V. Characterization of atherosclerotic plaques by magnetic resonance imaging. Ann NY Acad Sci 2000;902:173-186.
23. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res 2001;89:305-316.
24. Fayad ZA, Fuster V. The human high-risk plaque and its detection by magnetic resonance imaging. Am J Cardiol 2001;88:42E-45E.
25. Moody AR, Allder S, Lennox G, Gladman J, Fentem P. Direct magnetic resonance imaging of carotid artery thrombus in acute stroke. Lancet 1999;353:122-123.
26. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001;103: 415-422.
27. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation 1996;94:932-938.
28. Wasserman BA, Smith WI, Trout HH, Cannon RO, Balaban RS, Arai AE. Carotid artery atherosclerosis: In vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging - initial results. Radiology 2002;223:566-573.
29. Yuan C, Kerwin WS, Ferguson MS, Polissar N, Zhang SX, Cai JM, Hatsukami TS. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging 2002; 15:62-67.
30. Knopp MV, von Tengg-Kobligk H, Floemer F, Schoenberg SO. Contrast agents for MRA: future directions. J Magn Reson Imaging 1999;10:314-316.
31. Saeed M, Wendland MF, Higgins CB. Blood pool MR contrast agents for cardiovascular imaging. J Magn Reson Imaging 2000;12:890-898.
32. Corot C, Violas X, Robert P, Gagneur G, Port M. Comparison of different types of blood pool agents (P792, MS325, USPIO) in a rabbit MR angiography-like protocol. Invest Radiol 2003;38:311-319.
33. Huber ME, Paetsch I, Schnackenburg B, Bornstedt A, Nagel E, Fleck E, Boesiger P, Maggioni F, Cavagna FM, Stuber M. Performance of a new gadolinium-based intravascular contrast agent in free-breathing inversion-recovery 3D coronary MRA. Magn Reson Med 2003;49:115-121.
34. Lin W, Abendschein DR, Haacke EM. Contrast-enhanced magnetic resonance angiography of carotid arterial wall in pigs. J Magn Reson Imaging 1997;7:183-190.
35. Johansson LO, Bjerner T, Bjornerud A, Ahlstrom H, Tarlo KS, Lorenz CH. Utility of NC100150 injection in cardiac MRI. Acad Radiol 2002; 9(Suppl 1):S79-S81.
36. Johansson LO, Nolan MM, Taniuchi M, Fischer SE, Wickline SA, Lorenz CH. High-resolution magnetic resonance coronary angiography of the entire heart using a new blood-pool agent, NC100150 injection: comparison with invasive x-ray angiography in pigs. J Cardiovasc Magn Reson 1999;1:139-143.
37. Bentzen L, Vestergaard-Poulsen P, Nielsen T, Overgaard J, Bjornerud A, Briley-Saebo K, Horsman MR, Ostergaard L. Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor. Int J Radiat Oncol Biol Phys 2005;61:1208-1215.
38. 2* effects in vivo and ex vivo using iron oxide nanoparticles in steady state - dependence on blood volume and water exchange. Magn Reson Med 2002;47:461-471.
39. Krause MH, Kwong KK, Gragoudas ES, Young LH. MRI of blood volume with superparamagnetic iron in choroidal melanoma treated with thermotherapy. Magn Reson Imaging 2004;22:779-787.
40. Krause MH, Kwong KK, Xiong J, Gragoudas ES, Young LH. MRI of blood volume with MS 325 in experimental choroidal melanoma. Magn Reson Imaging 2003;21:725-732.
41. Li X, Rooney WD, Springer Jr CS. A unified magnetic resonance imaging pharmacokinetic theory: intravascular and extracellular contrast reagents. Magn Reson Med 2005;54:1351-1359.
42. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004;126:16316-16317.
43. Hyafil F, Laissy JP, Mazighi M, Tchetche D, Louedec L, Adle-Biassette H, Chillon S, Henin D, Jacob MP, Letourneur D, Feldman LJ. Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta: relationship between signal loss and macrophage infiltration. Arterioscler Thromb Vasc Biol 2006;26:176-181.
44. Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006;19:142-164.
45. Ruehm SG, Corot C, Vogt P, Cristina H, Debatin JF. Ultrasmall superparamagnetic iron oxide-enhanced MR imaging of atherosclerotic plaque in hyperlipidemic rabbits. Acad Radiol 2002;9(Suppl 1):S143-S144.
46. Schmitz SA, Taupitz M, Wagner S, Coupland SE, Gust R, Nikolova A, Wolf KJ. Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques: postmortem analysis of accuracy, inter-observer agreement, and pitfalls. Invest Radiol 2002;37:405-411.
47. Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001;14:355-361.
48. Sirol M, Itskovich VV, Mani V, Aguinaldo JG, Fallon JT, Misselwitz B, Weinmann HJ, Fuster V, Toussaint JF, Fayad ZA. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 2004;109:2890-2896.
49. Yancy AD, Olzinski AR, Hu TC, Lenhard SC, Aravindhan K, Gruver SM, Jacobs PM, Willette RN, Jucker BM. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling. J Magn Reson Imaging 2005;21:432-442.
50. Torchilin VP, Lukyanov AN, Gao ZG, Mazzola L. Polymer-lipid micelles as non-targeted and targeted pharmaceutical carriers. Abstr Pap Am Chem Soc 2002;224:U471-U472.
51. Accardo A, Tesauro D, Roscigno P, Gianolio E, Paduano L, D'Errico G, Pedone C, Morelli G. Physicochemical properties of mixed micellar aggregates containing CCK peptides and Gd complexes designed as tumor specific contrast agents in MRI. J Am Chem Soc 2004;126:3097-3107.
52. Anelli PL, Lattuada L, Lorusso V, Schneider M, Tournier H, Uggeri F. Mixed micelles containing lipophilic gadolinium complexes as MRA contrast agents. MAGMA 2001;12:114-120.
53. Hovland R, Glogard C, Aasen AJ, Klaveness J. Preparation and in vitro evaluation of a novel amphiphilic GdPCTA-[12] derivative; a micellar MRI contrast agent. Org Biomol Chem 2003;1:644-647.
54. Kimpe K, Parac-Vogt TN, Laurent S, Pierart C, Vander Elst L, Muller RN, Binnemans K. Potential MRI contrast agents based on micellar incorporation of amphiphilic bis(alkylamide) derivatives of [(Gd-DTPA)(H2O)](2-). Eur J Inorg Chem 2003:3021-3027.
55. Parac-Vogt TN, Kimpe K, Laurent S, Pierart C, Elst LV, Muller RN, Binnemans K. Godolinium DTPA-monoamide complexes incorporated into mixed micelles as possible MRI contrast agents. Eur J Inorg Chem 2004:3538-3543.
56. Trubetskoy VS. Polymeric micelles as carriers of diagnostic agents. Adv Drug Deliv Rev 1999;37:81-88.
57. Torchilin VP. Pharmacokinetic considerations in the development of labeled liposomes and micelles for diagnostic imaging. Q J Nucl Med 1997;41:141-153.
58. Vander Elst L, Van Haverbeke Y, Goudemant JF, Muller RN. Stability assessment of gadolinium complexes by P-31 and H-1 relaxometry. Magn Reson Med 1994;31:437-444.
59. Zhang X, Kirsch LE. An assessment of techniques for evaluating the physical stability of parenteral emulsions. PDA J Pharm Sci Technol 2003;57:300-315.
60. Winter PM, Caruthers SD, Yu X, Song SK, Chen J, Miller B, Bulte JW, Robertson JD, Gaffney PJ, Wickline SA, Lanza GM. Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med 2003;50:411-416.
61. Mani V, Briley-Saebo KC, Itskovich VV, Samber DD, Fayad ZA. Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn Reson Med 2006;55:126-135.
62. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 2003;100:6039-6044.
63. Nicolle GM, Toth E, Eisenwiener KP, Macke HR, Merbach AE. From monomers to micelles: investigation of the parameters influencing proton relaxivity. J Biol Inorg Chem 2002;7:757-769.
64. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990;175: 489-493.
65. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul 1996;13:245-255.
66. Harisinghani MG, Saksena MA, Hahn PF, King B, Kim J, Torabi MT, Weissleder R. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR Am J Roentgenol 2006;186:144-148.
67. Nishimura H, Tanigawa N, Hiramatsu M, Tatsumi Y, Matsuki M, Narabayashi I. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide. J Am Coll Surg 2006;202:604-611.
68. Saksena MA, Saokar A, Harisinghani MG. Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging. Eur J Radiol 2006;58:367-374.
69. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995;13:661-674.